Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab

Saved in:

Bibliographic Details
Published in:	Leukemia Vol. 27; no. 9; pp. 1949 - 1952
Main Authors:	Fink, A M, Böttcher, S, Ritgen, M, Fischer, K, Pflug, N, Eichhorst, B, Wendtner, C-M, Winkler, D, Bühler, A, Zenz, T, Staib, P, Mayer, J, Hensel, M, Hopfinger, G, Wenger, M, Fingerle-Rowson, G, Döhner, H, Kneba, M, Stilgenbauer, S, Busch, R, Hallek, M
Format:	Journal Article
Language:	English
Published:	London Nature Publishing Group UK 01-09-2013 Nature Publishing Group
Subjects:	692/699/67/1059/2325 692/699/67/1059/99 692/699/67/1990/283/1895 692/700/1750 Aged Aged, 80 and over Antibodies, Monoclonal, Murine-Derived - administration & dosage Antineoplastic Combined Chemotherapy Protocols - therapeutic use Cancer Research Chronic lymphocytic leukemia Complications and side effects Critical Care Medicine Cyclophosphamide Cyclophosphamide - administration & dosage Disease Progression Dosage and administration Drug therapy Female Fludarabine Gender Hematology Humans Intensive Internal Medicine Kinases Letter to the Editor Letters to the editor Leukemia Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy Leukemia, Lymphocytic, Chronic, B-Cell - genetics Leukemia, Lymphocytic, Chronic, B-Cell - mortality Male Medicine Medicine & Public Health Middle Aged Mutation Oncology Patients Prognosis Rituximab Treatment Outcome Vidarabine - administration & dosage Vidarabine - analogs & derivatives Germany
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Bibliography:	These authors contributed equally to this work and are therefore joint first authors of this study.
ISSN:	0887-6924 1476-5551
DOI:	10.1038/leu.2013.190